肺癌筛查中实性结节恶性预测的体积与直径阈值性能
结果显示<100 mm³或<6 mm直径结节的恶性风险与无结节者相当;体积排除阈值在同等阴性预测值下覆盖更多参与者,减少随访扫描。
要点
- 基线实性结节<100 mm³或<6 mm直径者恶性风险与无结节者无异。
- 体积<80 mm³排除阈值敏感性86.8%、特异性65.4%、NPV 99.2%。
- 直径<5 mm排除阈值敏感性93.4%、特异性24.64%、NPV 98.9%。
核心结论
- 基线低剂量CT实性结节<100 mm³或<6 mm直径不增加肺癌风险,与无结节者相当。
- 体积排除阈值与直径阈值阴性预测值等效,但覆盖更多参与者,减少间期扫描。
研究设计与样本
- 观察性研究,使用SUMMIT前瞻性纵向肺癌筛查研究数据。
- 基线低剂量CT使用计算机辅助检测软件(Veolity, MeVIS)半自动体积测量。
主要发现
- 基线实性结节粗恶性风险为3.8%(228/5929)。
- <6 mm长轴直径或<100 mm³体积结节恶性风险分别为0.88%和0.84%,无结节者为0.77%(p=0.4600和p=0.7932)。
- <80 mm³体积排除阈值敏感性86.8%、特异性65.4%、NPV 99.2%。
- <5 mm直径排除阈值敏感性93.4%、特异性24.64%、NPV 98.9%。
- <80 mm³阈值覆盖63.3%有基线实性结节参与者,<5 mm直径阈值覆盖24.0%。
关键数值与推荐
- 低风险结节排除阈值:5/6 mm长轴直径或80/100 mm³体积。
- 高风险结节纳入阈值:≥300 mm³或≥8 mm直径,伴或不伴Brock评分≥10%。
- 统计方法:Pearson χ2检验、McNemar检验、DeLong检验、Youden J统计量、bootstrap法计算净获益95% CI。
临床怎么用
- 基线实性结节<100 mm³或<6 mm直径可按无结节管理,避免过度随访。
- 体积阈值可替代直径阈值用于排除低风险结节,减少间期扫描数量。
- ≥8 mm实性结节建议结合Brock评分≥10%评估恶性风险以提升净获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prospective validation and comparison of the performance of nodule management protocols is limited. The aim of this study was to examine the performance of size and risk thresholds for assessing malignancy in solid nodules at baseline low-dose CT (LDCT) in a lung cancer screening (LCS) programme. METHODS: This was an observational study using data from the SUMMIT Study, a prospective longitudinal study investigating LDCT for LCS. Participants were 55-77 years old and met either the United States Preventative Services Task Force (2013) criteria or had a PLCOm2012 risk of ≥1.3%. LDCTs were reported using computer-aided detection software (Veolity, MeVIS) with semiautomated volumetry. Cancer outcomes were reported for solid nodules reported at baseline CT, with participants represented by the single largest solid nodule where more than one was present. Malignancy risk was stratified by long-axis diameter and volume using predefined size thresholds taken from British Thoracic Society and European Position statement guidelines: a 5/6 mm long axis diameter or 80/100 mm3 volume 'rule out' thresholds for low-risk nodules and ≥300 mm3 or ≥8 mm diameter with or without Brock score ≥10% 'Rule in' thresholds for high-risk nodules.Pearson's χ2 test was used to calculate statistical significance for nominal variables, McNemar's test for comparison of sensitivity/specificity and DeLong' test for comparison of areas under the receiver operating characteristic curve (AUROC). Optimal thresholds were determined with Youden's J statistic. Net benefit calculations were undertaken to compare the existing thresholds with 95% CIs calculated by bootstrap sampling. RESULTS: 11 355 participants were included. Crude risk of malignancy in solid nodules at baseline LDCT was 3.8% (228/5929). Risk of malignancy in solid nodules <6 mm long-axis diameter or <100 mm3 volume was equivalent to that in participants with no nodules at baseline LDCT (0.88% and 0.84% vs 0.77%, p=0.4600 and p=0.7932, respectively). A <80 mm3 volume and <5 mm diameter 'rule out' threshold achieved sensitivity 86.8% and 93.4%, specificity 65.4% and 24.64%, and negative predictive value (NPV) 99.2% and 98.9%, respectively. The <80 mm3 volume threshold encompassed 63.3% of participants with a baseline solid nodule compared with 24.0% by the <5 mm diameter threshold.For nodules ≥8 mm diameter, the addition of a risk score (Brock ≥10%) was associated with a significant net benefit when compared with using size threshold alone by net effect analysis (31.24; 95% CI 26.19 to 35.89). CONCLUSIONS: Solid nodules <100 mm3 or <6 mm diameter are not associated with increased risk of lung cancer compared with participants with no nodules at baseline LDCT. Volumetric rule-out thresholds achieve equivalent NPV to long-axis diameter thresholds while encompassing significantly more participants, reducing the number of interval scans required.
引用
- Creamer AW, Horst C, Prendecki R, et al. Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening. Thorax. 2025. PMID: 40456600. doi:10.1136/thorax-2024-222086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。